May 26, 2023 Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting
May 25, 2023 Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
May 10, 2023 Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
May 5, 2023 Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights
Apr 26, 2023 Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting
Apr 12, 2023 Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
Apr 12, 2023 Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Apr 12, 2023 Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders
Mar 28, 2023 Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium
Mar 3, 2023 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights